DCAD - Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomics

**开发新的蛋白质组技术以改善冠心病的早期诊断**Eliptica Limited提出了一项为期24个月的工作计划，该计划基于其创始人在Francis Crick研究所开发的人工智能增强、超快、低成本的基于质谱学(MS)的蛋白质组学新技术，只需要极少量的血浆就可以进行高质量的、种群规模的蛋白质组实验。该项目的目标是，在项目合作伙伴Bruker UK Limited和UK Biobank的支持下，证明我们的平台可以通过将人工智能应用于人类蛋白质组的大型参考基线来开发对心血管疾病的新见解，从而比目前更快、更准确地识别新的多蛋白面板生物标记物(MPPB)。我们的MPPB将很容易转换为血液测试，更准确地识别心血管疾病高危患者(例如，心脏病发作的迫在眉睫的风险)或潜在地识别最有可能从特定治疗中受益的患者子集。成立Eliptica是为了支持Precision Medicine(即确保正确的患者在正确的时间接受正确的治疗和医疗干预)。

**Developing novel proteomic techniques to improve early diagnostics for Coronary Heart Disease**Eliptica Limited proposes a 24 month programme of works based upon a new technique of AI-enhanced, ultrafast, low-cost mass-spectrometry (MS)-based proteomics that has been developed by its founders at the Francis Crick Institute and requires only very small amounts of blood plasma to perform high-quality, population scale, proteomic experiments.The project objective, with support from project partners Bruker UK Limited and UK Biobank, is to demonstrate that our platform can develop new insights into CVD through the application of AI to a large reference baseline of the human proteome and thus identify novel multi protein panel biomarkers (MPPB's) more quickly and accurately than is currently the case.Our MPPB's will be readily translatable into blood tests that more accurately identify patients at high risk of CVD (e.g. imminent risk of heart attack) or potentially identify the subset of patients most likely to benefit from a particular therapy. Eliptica was founded to enable Precision Medicine (i.e. to ensure the right patients receive the right treatments and medical interventions at the right time).